Ghrelin for neuroprotection in post-cardiac arrest coma: a 1-year follow-up of cognitive and psychosocial outcomes
European Heart Journal: Acute Cardiovascular Care · 2025
DOI: 10.1093/ehjacc/zuae119 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2025. Verfasst von Pauline van Gils und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurophysiology, Technical Medical Center, University of Twente, Drienerlolaan 5, 7522 NB Enschede, The Netherlands. Hauptthemen laut MEDLINE: Coma, Ghrelin, Cognition, Out-of-Hospital Cardiac Arrest. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council ZonMw, Dutch Heart Foundation.
Themen: Reanimation
Abstract (Originalsprache)
Aims
Effective treatments to improve brain recovery after cardiac arrest are needed. Ghrelin showed efficacy in experimental models and was associated with lower neuron-specific enolase levels in the clinical Ghrelin in Coma (GRECO) trial. Here, we present cognitive and psychosocial outcomes at 1-year follow-up. Methods and results GRECO was a Phase 2 multicentre, double-blind, randomized, placebo-controlled trial in comatose patients after cardiac arrest. The intervention was intravenous acyl-ghrelin 600 μg twice daily or placebo for 1 week, starting within 12 h after the arrest. Patients were assessed after 1 year using cognitive tests and questionnaires measuring participation, health-related quality of life, mood, and caregiver strain. Composite z-scores of the cognitive tests were computed by comparing the scores with those of a norm population and averaging the tests for memory, attention, and executive functioning separately. Groups were compared based on composite z-scores and cut-off scores for psychosocial outcomes. Of the 160 participants originally included, 66 of the 85 participants who survived to 1 year after OHCA completed the psychosocial and cognitive follow-up. The intervention group scored numerically higher across the cognitive domains compared with the control group, but the differences were not statistically significant (memory median = −0.850 vs. −1.385, U = 424.5, P = 0.587; attention median = −0.733 vs. −0.717, U = 420.5, P = 0.548; and executive functioning median = −0.311 vs. −0.482, U = 408.5, P = 0.323). There were significantly fewer signs of depression in the intervention group (U = 322.5, P = 0.014).
Conclusion
This predefined secondary analysis found that ghrelin treatment was associated with non-significantly but consistently better cognitive outcomes and significantly fewer signs of depression. This is in line with the primary outcomes. Clinical trial registration Clinicaltrialsregister.eu: EUCTR2018-000005-23-NL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neurophysiology, Technical Medical Center, University of Twente, Drienerlolaan 5, 7522 NB Enschede, The Netherlands.
- Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands.
- Limburg Brain Injury Center, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands.
- Department of Neurology, Medisch Spectrum Twente, Koningstraat 1, 7512 KZ Enschede, The Netherlands.
- Department of Medical Psychology, Medisch Spectrum Twente, Koningstraat 1, 7512 KZ Enschede, The Netherlands.
- Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands.
ORCID-Profile: Pauline van Gils
Förderung
- Dutch Research Council ZonMw
- Dutch Heart Foundation
Zitieren
APA
van Gils, P., Nutma, S., Meeske, K., van Heugten, C., van den Bergh, W., Foudraine, N., le Feber, J., Filius, M., van Putten, M., Beishuizen, B., Hofmeijer, J., & GRECO investigators (2025). Ghrelin for neuroprotection in post-cardiac arrest coma: a 1-year follow-up of cognitive and psychosocial outcomes. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuae119
Vancouver
van Gils P, Nutma S, Meeske K, van Heugten C, van den Bergh W, Foudraine N, et al. Ghrelin for neuroprotection in post-cardiac arrest coma: a 1-year follow-up of cognitive and psychosocial outcomes. European Heart Journal: Acute Cardiovascular Care. 2025. doi:10.1093/ehjacc/zuae119
BibTeX
@article{vanGils2025,
author = {van Gils, Pauline and Nutma, Sjoukje and Meeske, Karen and van Heugten, Caroline and van den Bergh, Walter and Foudraine, Norbert and le Feber, Joost and Filius, Margreet and van Putten, Michel and Beishuizen, Bert and Hofmeijer, Jeannette and GRECO investigators, GRECO investigators},
title = {Ghrelin for neuroprotection in post-cardiac arrest coma: a 1-year follow-up of cognitive and psychosocial outcomes},
journal = {European Heart Journal: Acute Cardiovascular Care},
year = {2025},
doi = {10.1093/ehjacc/zuae119}
}
EUVIMED